Grant: Master's Award: Canada Graduate Scholarships
University of Manitoba
$17,500.00
Chemogenomic determination of the mechanism of action of a novel drug against multidrug resistant Burkholderia cenocepacia complex
EF 2016-17
Résumé
The ability of drugs to treat many deadly infectious diseases is decreasing due to emerging antibiotic resistance. Some bacteria, such as Burkholderia cenocepacia show natural resistance to many currently used antibiotics. Specifically, infection by B. cenocepacia can be fatal for people with cystic fibrosis. Big pharmaceutical companies rarely invest in finding new antibiotics, as it can cost up to 1 billion dollars and take over 10 years to bring a new antibiotic to the clinic. Much of the work in developing effective antibiotics for doctors to prescribe currently falls to academics. The Cardona laboratory is developing a new faster antibiotic screening process that I will help to test. Thelab has a library of mutants, each deficient in one protein essential for growth, meaning they are more sensitive to antibiotics. This enhanced sensitivity makes it easier to pick out potential antibiotic targets and characterize how it works. Another lab has produced a new antibiotic, called C109, that kills B. cenocepacia, and although we have clues about how it works, the exact target is unknown. My research will be to use this new screening technique and previous clues to find a target for C109 in B. cenocepacia. I will treat the library with C109 and isolate the DNA from the surviving bacteria. I can then use DNA sequencing methods and bioinformatics to find which bacteria in the library were more sensitive to C109, which will be used to pinpoint how it acts in B. cenocepacia. This research will serve as a proof of concept that this technique can streamline drug characterization. Additionally, knowing exactly how C109 kills B. cenocepacia could lead to its use in the clinic to help treat dangerous lung infections in cystic fibrosis patients.
Programme
Master's Award: Canada Graduate Scholarships
Bénéficiaire
Emplacement
Manitoba, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
CIHR Funding Decisions Database
Tel que publié
Id
367131
Name
Hogan Andrew M
Region
Manitoba
Country
Canada
Orgtype
Institution Paid; Research Institution
Prcname2
Special Cases - Awards Programs
Projecttitle
Chemogenomic determination of the mechanism of action of a novel drug against multidrug resistant Burkholderia cenocepacia complex
Programtype2
Studentship Programs
Orgnameinp2
University of Manitoba
Cihramount2
$17,500
Cihrequipment2
$0
Programname2
Master's Award: Canada Graduate Scholarships
Keyworddelim
Bioinformatics; Burkholderia Cenocepacia Complex; Chemogenomics; Confocal Microscopy; Cystic Fibrosis; Essential Genes; Ftsz; Gene Regulation; Next-Generation Sequencing; Novel Antibiotics
Abstract
The ability of drugs to treat many deadly infectious diseases is decreasing due to emerging antibiotic resistance. Some bacteria, such as Burkholderia cenocepacia show natural resistance to many currently used antibiotics. Specifically, infection by B. cenocepacia can be fatal for people with cystic fibrosis. Big pharmaceutical companies rarely invest in finding new antibiotics, as it can cost up to 1 billion dollars and take over 10 years to bring a new antibiotic to the clinic. Much of the work in developing effective antibiotics for doctors to prescribe currently falls to academics. The Cardona laboratory is developing a new faster antibiotic screening process that I will help to test. Thelab has a library of mutants, each deficient in one protein essential for growth, meaning they are more sensitive to antibiotics. This enhanced sensitivity makes it easier to pick out potential antibiotic targets and characterize how it works. Another lab has produced a new antibiotic, called C109, that kills B. cenocepacia, and although we have clues about how it works, the exact target is unknown. My research will be to use this new screening technique and previous clues to find a target for C109 in B. cenocepacia. I will treat the library with C109 and isolate the DNA from the surviving bacteria. I can then use DNA sequencing methods and bioinformatics to find which bacteria in the library were more sensitive to C109, which will be used to pinpoint how it acts in B. cenocepacia. This research will serve as a proof of concept that this technique can streamline drug characterization. Additionally, knowing exactly how C109 kills B. cenocepacia could lead to its use in the clinic to help treat dangerous lung infections in cystic fibrosis patients.
Competitiondate
201612
Approvedterm2
1 yr 0 mth
Pinamesdelim
Hogan, Andrew M
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $17,500~ $0~